[{"id":"a3330799-3a3c-4c3b-bada-534a183f734f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05382338","created_at":"2022-05-19T11:56:15.604Z","updated_at":"2025-02-25T15:12:50.886Z","phase":"Phase 3","brief_title":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","source_id_and_acronym":"NCT05382338","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN • GLI2","pipe":" | ","alterations":" TP53 wild-type","tags":["MYCN • GLI2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • vincristine • lomustine • mesna"],"overall_status":"Suspended","enrollment":" Enrollment 225","initiation":"Initiation: 02/20/2023","start_date":" 02/20/2023","primary_txt":" Primary completion: 12/20/2027","primary_completion_date":" 12/20/2027","study_txt":" Completion: 12/20/2027","study_completion_date":" 12/20/2027","last_update_posted":"2025-02-13"},{"id":"b3fcd5d4-2376-4a44-a782-f5af77183569","acronym":"LEAHRN","url":"https://clinicaltrials.gov/study/NCT02724579","created_at":"2021-01-18T13:20:08.012Z","updated_at":"2025-02-25T15:10:23.410Z","phase":"Phase 2","brief_title":"Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma","source_id_and_acronym":"NCT02724579 - LEAHRN","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN • CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["MYCN • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • vincristine • lomustine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 11/17/2017","start_date":" 11/17/2017","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-13"},{"id":"f3d782d2-7f3d-4ad2-b8d5-99602c17c34a","acronym":"SONOBIRD","url":"https://clinicaltrials.gov/study/NCT05902169","created_at":"2023-06-13T17:08:12.284Z","updated_at":"2024-07-02T16:34:26.706Z","phase":"Phase 3","brief_title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","source_id_and_acronym":"NCT05902169 - SONOBIRD","lead_sponsor":"CarThera","biomarkers":" BRAF • IDH1","pipe":" | ","alterations":" BRAF mutation • IDH1 R132H • IDH1 R132","tags":["BRAF • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • temozolomide • lomustine"],"overall_status":"Recruiting","enrollment":" Enrollment 560","initiation":"Initiation: 01/29/2024","start_date":" 01/29/2024","primary_txt":" Primary completion: 01/28/2028","primary_completion_date":" 01/28/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-06-12"},{"id":"17106019-1f09-43d1-b5ca-ce2f02cc6783","acronym":"GLIOSTAR","url":"https://clinicaltrials.gov/study/NCT04573192","created_at":"2023-06-23T01:16:24.218Z","updated_at":"2024-07-02T16:35:10.988Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression","source_id_and_acronym":"NCT04573192 - GLIOSTAR","lead_sponsor":"Philogen S.p.A.","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • Fibromun (onfekafusp alfa)"],"overall_status":"Recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 02/19/2021","start_date":" 02/19/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-08"},{"id":"6f4512bb-8afc-4c34-a25f-189b0c54dc26","acronym":"GLIOASTRA","url":"https://clinicaltrials.gov/study/NCT05304663","created_at":"2022-03-31T17:52:52.829Z","updated_at":"2024-07-02T16:35:10.960Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression","source_id_and_acronym":"NCT05304663 - GLIOASTRA","lead_sponsor":"Philogen S.p.A.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • Fibromun (onfekafusp alfa)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-08"},{"id":"50f8b205-06c7-4e3e-b459-1ebbfce2f273","acronym":"","url":"https://clinicaltrials.gov/study/NCT04910022","created_at":"2021-06-02T20:57:18.421Z","updated_at":"2024-07-02T16:35:14.620Z","phase":"Phase 1/2","brief_title":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT04910022","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" EGFR • IDH1 • IDH2 • MGMT • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • IDH1 • IDH2 • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • itareparib (NMS-293)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-15"},{"id":"5f5a65f2-c9f4-4073-a80b-3cfdbd4c58d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03382977","created_at":"2021-01-18T16:41:38.687Z","updated_at":"2024-07-02T16:35:14.613Z","phase":"Phase 1/2","brief_title":"Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects","source_id_and_acronym":"NCT03382977","lead_sponsor":"VBI Vaccines Inc.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • carmustine • VBI-1901"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 12/06/2017","start_date":" 12/06/2017","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-03-15"},{"id":"a0e00cfa-2eb4-4439-8a06-39293232dc5b","acronym":"Actuate 1801","url":"https://clinicaltrials.gov/study/NCT03678883","created_at":"2021-01-18T18:02:27.392Z","updated_at":"2024-07-02T16:35:15.452Z","phase":"Phase 2","brief_title":"9-ING-41 in Patients With Advanced Cancers","source_id_and_acronym":"NCT03678883 - Actuate 1801","lead_sponsor":"Actuate Therapeutics Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • albumin-bound paclitaxel • irinotecan • pegylated liposomal doxorubicin • lomustine • elraglusib (9-ING-41) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-03-11"},{"id":"bd470247-33b7-45c3-a313-a7729d609e0e","acronym":"NRG-BN011","url":"https://clinicaltrials.gov/study/NCT05095376","created_at":"2021-10-27T15:53:22.431Z","updated_at":"2024-07-02T16:35:23.915Z","phase":"Phase 3","brief_title":"Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma","source_id_and_acronym":"NCT05095376 - NRG-BN011","lead_sponsor":"NRG Oncology","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH1 R132H • IDH1 R132","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine"],"overall_status":"Recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 08/08/2026","primary_completion_date":" 08/08/2026","study_txt":" Completion: 08/08/2031","study_completion_date":" 08/08/2031","last_update_posted":"2024-01-10"},{"id":"aa1cebd7-d5ff-467e-9ba4-a573015d172c","acronym":"PersoMed-I","url":"https://clinicaltrials.gov/study/NCT04402073","created_at":"2021-01-18T21:14:10.343Z","updated_at":"2024-07-02T16:35:26.623Z","phase":"Phase 2","brief_title":"Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma","source_id_and_acronym":"NCT04402073 - PersoMed-I","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" TP53 • BRCA2 • MYCN","pipe":" | ","alterations":" TP53 wild-type • MYCN amplification","tags":["TP53 • BRCA2 • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • vincristine • lomustine • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 205","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2023-12-11"},{"id":"d393c421-1cb3-4ec6-9581-ed088473191d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04762069","created_at":"2021-02-21T13:52:16.258Z","updated_at":"2024-07-02T16:35:37.087Z","phase":"Phase 2","brief_title":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","source_id_and_acronym":"NCT04762069","lead_sponsor":"CNS Pharmaceuticals, Inc.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • lomustine • berubicin (RTA 744)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 05/18/2021","start_date":" 05/18/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-09-13"},{"id":"5aa9101f-5e17-4f18-aed0-af281c1f2b88","acronym":"R-2","url":"https://clinicaltrials.gov/study/NCT05898451","created_at":"2023-06-12T16:09:02.706Z","updated_at":"2024-07-02T16:35:45.921Z","phase":"Phase 2","brief_title":"Effect of Refnot on Immunity in Cancer Patients","source_id_and_acronym":"NCT05898451 - R-2","lead_sponsor":"Refnot-Pharm Ltd","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • dacarbazine • lomustine • Zadaxin (thymalfasin)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 06/04/2009","start_date":" 06/04/2009","primary_txt":" Primary completion: 11/01/2011","primary_completion_date":" 11/01/2011","study_txt":" Completion: 11/01/2011","study_completion_date":" 11/01/2011","last_update_posted":"2023-06-12"},{"id":"2325ad67-a6c7-40b4-b0a4-40263229ded9","acronym":"RIGOLETTO","url":"https://clinicaltrials.gov/study/NCT04933942","created_at":"2021-06-22T15:52:35.716Z","updated_at":"2024-07-02T16:35:47.227Z","phase":"Phase 2","brief_title":"Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma","source_id_and_acronym":"NCT04933942 - RIGOLETTO","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH1 R132H • IDH1 R132","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • Nplate (romiplostim)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 12/19/2022","primary_completion_date":" 12/19/2022","study_txt":" Completion: 12/19/2022","study_completion_date":" 12/19/2022","last_update_posted":"2023-05-24"},{"id":"4f03f71b-4bd9-45f1-980c-fad65248deab","acronym":"","url":"https://clinicaltrials.gov/study/NCT01775475","created_at":"2021-01-29T07:04:14.975Z","updated_at":"2024-07-02T16:36:02.736Z","phase":"Phase 2","brief_title":"Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01775475","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • lomustine • Matulane (procarbazine hydrochloride) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 09/15/2016","start_date":" 09/15/2016","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 07/15/2021","study_completion_date":" 07/15/2021","last_update_posted":"2022-10-10"},{"id":"ac5a9972-ce4c-4577-916a-237f2ad4da29","acronym":"REGOMA","url":"https://clinicaltrials.gov/study/NCT02926222","created_at":"2021-07-05T16:58:13.099Z","updated_at":"2025-02-25T17:23:19.717Z","phase":"Phase 2","brief_title":"Regorafenib in Relapsed Glioblastoma","source_id_and_acronym":"NCT02926222 - REGOMA","lead_sponsor":"Istituto Oncologico Veneto IRCCS","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • lomustine"],"overall_status":"Completed","enrollment":" Enrollment 119","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 07/01/2017","primary_completion_date":" 07/01/2017","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2022-09-09"},{"id":"e2ddae45-902b-4062-806c-6a7847dab82d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02066220","created_at":"2021-01-18T09:31:00.993Z","updated_at":"2024-07-02T16:36:11.940Z","phase":"Phase 2/3","brief_title":"International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","source_id_and_acronym":"NCT02066220","lead_sponsor":"Universitätsklinikum Hamburg-Eppendorf","biomarkers":" MYCN","pipe":"","alterations":" ","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • vincristine • lomustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2022-04-19"},{"id":"5e9a50d4-ba91-4959-9e13-d63c3c83ed70","acronym":"STELLAR","url":"https://clinicaltrials.gov/study/NCT03025893","created_at":"2021-01-18T14:53:33.013Z","updated_at":"2024-07-02T16:36:31.601Z","phase":"Phase 2/3","brief_title":"A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme","source_id_and_acronym":"NCT03025893 - STELLAR","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • lomustine"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/31/2018","start_date":" 08/31/2018","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2021-04-19"},{"id":"aeb5b4e9-80f4-4bee-803f-d74c5f46774a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02678975","created_at":"2021-01-18T13:03:47.894Z","updated_at":"2024-07-02T16:36:33.082Z","phase":"Phase 2/3","brief_title":"Disulfiram in Recurrent Glioblastoma","source_id_and_acronym":"NCT02678975","lead_sponsor":"Sahlgrenska University Hospital, Sweden","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 01/15/2021","primary_completion_date":" 01/15/2021","study_txt":" Completion: 01/15/2021","study_completion_date":" 01/15/2021","last_update_posted":"2021-03-18"},{"id":"be8c91be-539b-4b14-a9c2-42922b51a31c","acronym":"RTOG Foundation 3508","url":"https://clinicaltrials.gov/study/NCT02343406","created_at":"2021-01-18T11:08:20.656Z","updated_at":"2024-07-02T16:36:44.845Z","phase":"Phase 2","brief_title":"Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas","source_id_and_acronym":"NCT02343406 - RTOG Foundation 3508","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • EGFRvIII mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 266","initiation":"Initiation: 02/17/2015","start_date":" 02/17/2015","primary_txt":" Primary completion: 06/24/2019","primary_completion_date":" 06/24/2019","study_txt":" Completion: 06/24/2019","study_completion_date":" 06/24/2019","last_update_posted":"2020-05-22"},{"id":"a3a58e02-f2ed-4180-b7f9-05fe3794ffbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01860638","created_at":"2021-01-18T08:19:06.557Z","updated_at":"2024-07-02T16:37:11.124Z","phase":"Phase 2","brief_title":"A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma","source_id_and_acronym":"NCT01860638","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • lomustine"],"overall_status":"Completed","enrollment":" Enrollment 296","initiation":"Initiation: 08/19/2013","start_date":" 08/19/2013","primary_txt":" Primary completion: 01/13/2017","primary_completion_date":" 01/13/2017","study_txt":" Completion: 05/05/2017","study_completion_date":" 05/05/2017","last_update_posted":"2018-04-30"}]